In 2015, a global consensus solidified around the goal of ending AIDS as a public health threat by 2030. Major tools in achieving these goals are attaining global HIV testing, treatment, and viral suppression targets articulated in the Joint United Nations Programme on HIV/AIDS (UNAIDS) 90-90-90 targets, which call for ensuring that by 2020:
These goals and the clinical and public health consensus around them are based on two clinical concepts that by the end of 2015 had achieved universally accepted clinical validation. These concepts are treatment as prevention (TasP) and pre-exposure prophylaxis (PrEP). TasP is the idea that HIV-positive persons whose virus is suppressed on ART are extremely unlikely to transmit HIV to sex and drug partners. PrEP is the use of ART by uninfected individuals to prevent HIV infection from sexual contact with an HIV-infected partner. Both of these concepts have been clinically validated in a number of large, randomized, controlled clinical trials.
TasP and PreP, then, join HIV testing as the three clinical pillars supporting current strategies to curb and eventually eliminate HIV and AIDS. Behavioral, clinical, and structural interventions to expand the use of PrEP and the achievement of TasP (that is, increasing the proportion of HIV-positive persons who are in care, on ART, and with virologic suppression) are integral to achieving the globally accepted goal of ending the epidemic in the next two decades.
This CME-accredited activity addresses these interventions within the context of:
This online activity features: